Galderma Group
CHF 160.55Change from previous close: −0.16%Absolute change: −CHF 0.25
At a glance
- Revenue growth
- +18.04%
- 2025 vs 2024
- Net income growth
- +165.37%
- 2025 vs 2024
- Net margin
- 11.7%
- 2024: 5.2%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 572 | 634 | 551 | 400 | 88.0 | 331 | -166 |
| Depreciation and amortization | 164 | 146 | 158 | 130 | 119 | 122 | 114 |
| Capital expenditure | -56.0 | -70.0 | -43.0 | -64.0 | -64.0 | -92.0 | -29.0 |
| Investing cash flow | -64.0 | -81.0 | -73.0 | -146 | -180 | -71.0 | -103 |
| Financing cash flow | -454 | -233 | -495 | -181 | 123 | -146 | 288 |
| Dividends paid | -104 | — | -41.0 | — | — | — | — |
| Share repurchases | -302 | -40.0 | -323 | -15.0 | — | — | — |
| Debt issued | 607 | 243 | 1,165 | 633 | 2,968 | 159 | 697 |
| Debt repaid | -651 | -414 | -1,287 | -802 | -4,975 | -578 | -1,147 |
| Effect of exchange rates | 4.0 | 2.0 | 18.0 | — | -14.0 | 8.0 | -8.0 |
| Net change in cash | 59.0 | 322 | 1.0 | 72.0 | 17.0 | 123 | 11.0 |
| Free cash flow | 516 | 564 | 508 | 336 | 24.0 | 239 | -195 |
| Levered free cash flow | 410 | 465 | 440 | 225 | -93.4 | 136 | — |